Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Rafina Innovations's Total Liabilities for the quarter that ended in Mar. 2019 was $0.89 Mil. Rafina Innovations's Total Assets for the quarter that ended in Mar. 2019 was $0.30 Mil.
Therefore, Rafina Innovations's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2019 was 2.95.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Rafina Innovations Liabilities-to-Assets Related Terms
Rafina Innovations Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Rafina Innovations's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VICA vs RMSL, GTHP, DCTH: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Rafina Innovations's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rafina Innovations Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rafina Innovations's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Rafina Innovations's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Rafina Innovations's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2018 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rafina Innovations (VICA) has a Liabilities-to-Assets of 2.95 as of Mar. 2019. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rafina Innovations and its competitors.
Is Rafina Innovations' Liabilities-to-Assets too high?
Rafina Innovations' current Liabilities-to-Assets is 2.95. Overall, Rafina Innovations has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Rafina Innovations' Liabilities-to-Assets compare to RMSL and GTHP?
Rafina Innovations' Liabilities-to-Assets of 2.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rafina Innovations and its competitors. Rafina Innovations's current Liabilities-to-Assets is 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rafina Innovations stock overvalued right now?
Rafina Innovations (VICA) has a current Liabilities-to-Assets of 2.95. The current Liabilities-to-Assets is 2.95. Rafina Innovations' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Rafina Innovations (VICA), the current Liabilities-to-Assets is 2.95 as of Mar. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rafina Innovations Inc through its subsidiaries is involved in the development of monitoring technologies, set up of rehabilitation centers, development of intellectual property related to everyday fields such as healthcare, sports, automotive and gaming as well as the creation of full-service Prosthetics and Orthotics and Diabetic foot clinics chain in Europe and the Middle East. The firm's main products include Flexisense technology and Rehabilitation clinics etc. It has Clinics and Technology operating segments and derives a majority of its revenues from Clinics segment.
12GF Score
Get the complete analysis for VICA
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VICA has been successfully added to your 
